Clinical trial
ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In…
NCT00247481 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00247481 |
|---|---|
| Title | ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer |
| Official title | A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, Docetaxel |
| Enrollment | 77 |
| Start date | Sep 1, 2002 |
| Completion | Jun 1, 2005 |
| First posted | Nov 2, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: